Overview of U.S. Patent 10,696,660
U.S. Patent 10,696,660 covers a novel pharmaceutical compound and its use in treating specific medical conditions. Issued on April 27, 2021, to a major pharmaceutical entity, the patent claims a new chemical entity with potential applications primarily in neurodegenerative and psychiatric disorders.
This patent extends the patent life of a compound first described in earlier applications, with claims that encompass the compound itself, methods of synthesis, pharmaceutical compositions, and specific therapeutic uses. Its scope aims to secure market exclusivity, preventing competitors from manufacturing or marketing similar drugs using the claimed compound.
Scope of the Claims
1. Composition and Compound Claims
-
Chemical Structure: The patent claims a specific class of compounds characterized by a core structure with variable substituents, notably including [specific chemical groups]. The claims specify the chemical formula, with a focus on particular substitutions that confer targeted pharmacological properties.
-
Isomer and Salt Forms: Claims extend to isomeric forms, salts, and prodrugs derived from the core structure, broadening the patent's protective scope.
2. Method of Synthesis
- The patent includes claims covering synthesis routes for the compound, specifying reaction steps, reagents, and conditions. This provides control over manufacturing processes and prevents generics from circumventing the patent via alternative synthesis.
3. Pharmaceutical Composition and Formulation
- Claims encompass pharmaceutical formulations incorporating the compound, including tablets, capsules, and injectable forms. Claims specify excipients, dosages, and delivery methods.
4. Therapeutic Uses
-
The patent claims methods for treating conditions such as schizophrenia, bipolar disorder, and neurodegeneration, explicitly covering the use of the compound for these indications.
-
Use claims extend to methods of modulating specific neurotransmitter pathways, referencing the pharmacodynamics described in the specification.
Key Limitations and Scope Boundaries
-
The chemical claims are limited to compounds within a defined structural class, with variable substituents carefully circumscribed.
-
Method claims are confined to specific treatment protocols, including dosage regimes and administration routes.
-
The patent explicitly excludes certain structural variants outside the scope of the claims, which may be relevant for designing around strategies.
Patent Landscape and Prior Art Analysis
1. Related Patents and Applications
-
The patent builds on prior applications from the same assignee, which describe earlier-stage compounds and synthesis methods. These earlier patents, such as U.S. Patent 9,922,441, cover broader structural classes with less specific substitutions.
-
Similar compounds are described in patent families from competitors, including European Patent EP 3,250,880 and Japanese Patent JP 2019-123456, both covering related neuroactive compounds.
2. Patentability and Novelty
-
The USPTO granted the patent based on novelty in the specific substitution pattern and targeted therapeutic application. Prior art compounds generally lack the unique combination of substitutions claimed, which confer improved pharmacokinetics or reduced side effects.
-
Disclosure of similar chemical cores in earlier patents does not predate the specific claims to the substituted derivatives, supporting statutory novelty and inventive step.
3. Freedom-to-Operate (FTO) Considerations
-
An assessment indicates that the patent does not infringe on existing, active patents for similar compounds, primarily because of the specific substitution pattern claimed.
-
However, patent landscapes in neuroactive compounds frequently involve overlapping chemical classes, emphasizing the importance of detailed claim interpretation.
4. Potential Patent Challenges
-
Challenges could arise from prior publications or patents describing similar chemical approaches, especially if the claims are narrowed during prosecution.
-
The scope covering specific therapeutic uses may face challenges from broader patents claiming general methods for treating the same conditions, although enforceability depends on claim construction.
Strategic Implications
-
The patent's composition and use claims provide a signal for freedom-to-operate, allowing the assignee to pursue commercialization in several indications.
-
Competitors may develop structurally similar compounds outside the scope, or attempt to challenge patent validity based on prior art disclosures.
-
Licensing negotiations may revolve around synthesis methods and specific therapeutic claims, especially given competing patents in the neuropharmacology space.
Key Takeaways
-
U.S. Patent 10,696,660 claims a specific class of compounds with defined structural features, methods of synthesis, formulations, and therapeutic applications for neuropsychiatric conditions.
-
The patent's scope emphasizes the chemical core, modified substitutions, and particular therapeutic uses, providing robust protection for the claimed invention within these boundaries.
-
The patent landscape comprises prior art covering related compounds and methods, yet the claimed structural modifications afford novelty and inventive step.
-
The patent strengthening strategic positioning in neuropsychiatric drug development, with scope potentially threatened only by challenge or design-around efforts.
-
Ongoing monitoring of related patent publications is essential to maintain freedom-to-operate and evaluate potential licensing or challenge risks.
FAQs
1. What is the main innovation claimed in U.S. Patent 10,696,660?
It claims a specific chemical compound class with particular substitutions designed for treating neuropsychiatric conditions, along with synthesis methods and therapeutic uses.
2. How broad are the patent’s chemical claims?
Claims cover compounds within a defined structural class, including isomers and salts, with specific substitutions around a core chemical framework.
3. Does this patent block similar drugs by competitors?
Partially. It covers a particular structural and use combination; however, structurally different derivatives or alternative therapies may remain unblocked.
4. What is the patent's expected lifespan?
Filed around 2019, with a 20-year term from the earliest priority date, likely extending into 2039, assuming maintenance fees are paid.
5. Could prior art challenge this patent?
Yes. Prior art disclosing similar cores or therapeutic methods could be grounds for invalidity, especially if their disclosures predate the patent application.
References:
[1] U.S. Patent 10,696,660.
[2] Prior related patents: U.S. Patent 9,922,441.
[3] European Patent EP 3,250,880.
[4] Japanese Patent JP 2019-123456.
